NasdaqGS:NVCRMedical Equipment
A Look At NovoCure (NVCR) Valuation After Raised 2026 Revenue Guidance And Q1 Beat
NovoCure (NVCR) has drawn fresh attention after reporting first quarter 2026 revenue that exceeded expectations and raising its full-year revenue outlook to a range of US$690 million to US$710 million.
See our latest analysis for NovoCure.
The strong Q1 update and higher 2026 revenue guidance have arrived alongside a sharp shift in sentiment, with a 62.61% 1 month share price return and a 65.98% 3 month share price return contrasting with a 3.50% 1 year total shareholder return decline. This...